eurotoxicity of cancer treatment: Neurocognitive dysfunction and underlying mechanisms
- Conditions
- acute lymphoblastic leukemia (ALL)blood cancer10024324
- Registration Number
- NL-OMON29855
- Lead Sponsor
- niversiteit Leiden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 338
Inclusion Criteria
Being treated for ALL according to DCLSG protocol ALL 5 (1979 - 1984) or according to DCLSG protocol ALL 6 (1984 - 1988)
Exclusion Criteria
Use of centrally acting drugs, active psychiatric disease or symptoms, pre-existing CNS disorders, insufficient mastery of Dutch language.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Outcomes will be a neuropsychological deficit profile, a profile of structural<br /><br>and functional integrity of neural networks and descriptions of quality of<br /><br>life. Profiles of the different patient groups and controls will be<br /><br>contrasted. </p><br>
- Secondary Outcome Measures
Name Time Method <p>Coincidental findings of secundary tumors after radiation will be registered. </p><br>